CARLSBAD, Calif., May 17, 2017 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) (“ISCO” or “the Company”), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, today provided a business update and announced operating results for the three months ended March 31, 2017.
“This was a successful quarter for us. We were able to grow our sales and to move forward our R&D activities. As a result we have significantly decreased our cash burn while continuing our clinical trial. These outcomes give us confidence in the Company’s future,” said Andrey Semechkin, PhD., CEO and Co-Chairman of ISCO.